Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women

25 de novembro de 2015 atualizado por: Helena Kopp Kallner, Karolinska Institutet

Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women

Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before use of the crème and at the end of a 10 days crème-usage (day 8-10), as well as 10 days after (9-11 days) finished crème-usage.

The hypothesis is that lactobacilli can survive in the intimate area of postmenopausal women with use of a probiotic creme.

Visão geral do estudo

Descrição detalhada

The rational for using probiotics is that the humans are colonized by a numbers of microorganisms from birth. These microorganisms are the natural flora of the human body. This bacterial ecology may be imbalanced due different circumstances: excessive hygiene, use of antibiotics or other drugs, use of alcohol, smoking, stress, diabetes and many other factors. The natural bacterial flora in the external part of the genital tract might be promoted by help of intimate products containing probiotics.

The study objectives Generate more information on the use of the Probiotic Intimate Crème regarding feeling of dryness and freshness in the intimate area, as well as to evaluate the Lactobacillus flora and presence of coliform bacteria in respect to E. coli in the intimate area of women before and at the end of a 10 days crème-usage (day 8-10), as well as 10 (9-11) days after finished crème-usage.

The primary endpoint of the study Presence of at least one LN bacteria strain in the intimate area of women in the intervention group compared to the intimate area of women in the control group at the end of a 10 days crème-usage (Day 8-10), as well as 10 (9-11) days after finished crème-usage. The primary endpint will be measured by bacterial Culture.

None-parametric statistical analyses.

Secondary endpoints Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).

Obtain information about the subjective feeling of dryness and freshness in the intimate of women before and at the end of the 10 days crème-usage (Day 8-10), as well as 10 days after finished crème-usage (9-11 days after).

Only descriptive statistics.

Blinding The active and comparative test product will be filled into white tubes with identical appearance.

The study will be conducted with double-blind design when neither the personnel at the clinic and the participants knows which product they are submitted/received. The study will also be blinded for the laboratory personnel analyzing the samples.

Randomization procedure The women will be randomly assigned to active or comparative test products. Based on a computer-generated list, before start of the study, nine tubes containing Probiotic Intimate Crème (the active product) and 9 tubes containing Soothing crème (the control product) will be randomly assigned to a number between 1 to 18, and the tubes labeled with the numbers. The numbered but otherwise visually identical tubes will delivered to the clinic before start of the study.

During the first visit, the participants will receive a tube consecutively in numerical order, as they are included in the study, i.e. according to their participant number.

The computer-generated randomization list and the product labeling will be carried out by people who don't have direct contact with the study participants.

Sample collection

Vaginal samples:

The samples will be taken by rolling sterile swabs over the upper third part of the lateral vaginal wall.

Labial samples:

For labial sampling, on the left side of the vulva near the vaginal orifice, the labia minor and major will be held apart and a sterile swab will be gently rubbed back and forth five times during rotation. The labial examination area will be approximately 2 cm2.

The swabs will then be placed in a prepared transport medium and sent to laboratory for analyses.

6.12. Study outline

Visit 1:

  1. Women visiting the clinic will be recruited to the study. After obtained information (Appendix 1) and signed informed consent the women will be clinically examined for any clinical symptoms of Candida vaginitis (ocular examination) and bacterial vaginosis (Amsel's criteria). The dryness of the mucus membranes will be also examined and the vaginal pH measured using a pH-stick.
  2. Women fulfilling the inclusion criteria will be randomized to 10 days use of test product (Probiotic Intimate Crème) or control product (Soothing Cream, ACO); 2 times daily, every morning and evening at bed time.
  3. The women will receive detailed instructions about how to use the study products.
  4. They will also asked to return the empty tube or remaining product at the end of study (Visit 3)
  5. The women will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale.
  6. Samples with sterile swabs will be collected from vagina, labia and perineum (Sample 1-L, Sample 1-V) and sent to an independent laboratory for analyses.

Visit 2:

  1. The 8th-10th day of the intimate crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH.
  2. They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
  3. Vaginal and labial swabs will be collected (Sample 2-L, Sample 2-V) and send to an independent laboratory for analyses.

Visit 3:

  1. 9-11 days after the 10 days crème-usage period, the women will return to the clinic. The dryness of their mucus membranes will be clinically examined and the vaginal pH measured.
  2. They will answer a questioner regarding their subjective feeling of dryness and freshness in their intimate are and rate their feeling on a ten-point scale. They will also answer questions regarding their purchase intentions and intentions to recommend the product to other women.
  3. Vaginal and labial swabs will be collected. (Sample 3-L, Sample 3-V) and sent to an independent laboratory for analyses.

During each visit, data will be recorded in the CRF.

Tipo de estudo

Intervencional

Inscrição (Real)

18

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Stockholm, Suécia, 18288
        • Dept of Obstetrics and Gynecology, Dnderyds Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

45 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • healthy women 45-65 years old
  • with subjective dryness in the intimate area
  • postmenopausal with last menstruation more than or equal to 3 years prior to entering the study
  • being willing to abstain sexual intercourse during the study period

Exclusion Criteria:

  • yeast infection or bacterial vaginosis
  • use of antibiotics or antifungals
  • use of estrogen
  • participation in Another study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Probiotic creme
Women receing probiotic creme
Probiotic creme applied
Outros nomes:
  • Ellen AB
Comparador de Placebo: placebo
Women receiving a moisturizer
Creme without probiotics applied in same manner

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Presence of at least one LN bacteria strain in the intimate area of women in the intervention group
Prazo: the end of a 10 days crème-usage
Bacterial Culture of LN bacterial strains
the end of a 10 days crème-usage

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area
Prazo: at the end of creme usage and 10 days after finished crème-usage (9-11 days after).
Measured by bacterial Culture and subtyping by PCR
at the end of creme usage and 10 days after finished crème-usage (9-11 days after).
subjective feeling of dryness and freshness in the intimate of women
Prazo: the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)
Assessed through self adminstered questionnair with grading of feeling of dryness and freshness on a scale from 0 (no dryness and feeling fresh) to 5 (max dryness and absolutely not feeling fresh)
the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Helena Kopp Kallner, MD, PhD, Karolinska Institutet

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2013

Conclusão Primária (Real)

1 de março de 2014

Conclusão do estudo (Real)

1 de março de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

21 de novembro de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de junho de 2014

Primeira postagem (Estimativa)

12 de junho de 2014

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

26 de novembro de 2015

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de novembro de 2015

Última verificação

1 de novembro de 2015

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • KI DS 2013

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever